Next generation sequencing technologies and advanced mass spectrometry platforms coupled with advanced imaging facilities, set the basis for personalized and stratified drug discovery and development. The following coreunits will be established in the context of pMedGR, to address the needs of both the industrial and academic sector in implementing personalized medicine.
Personalised Genomics & Transcriptomics Unit
The Unit will provide services and support in high-throughput, genome wide research, including genomic applications (whole genome sequencing, exome sequencing, whole genome mapping, genotyping etc), transcriptomic (RNA-Seq, smallRNA-Seq), epigenomic (MeDIP-Seq, ChIP-Seq, bisulfide sequencing etc), metagenomic and genotyping services.
Proteomics and Metabolomics Unit
The Unit will provide the following services:
improved sample separation and sensitivity
accurate quantization in parallel with identification
high-throughput analysis of proteins and metabolites
metabolic profiling and fingerprinting
Mass Cytometry (CyTOF) Unit
Using the 3rd generation Helios cytometer, allows the simultaneous identification of over 150 different parameters at a single cell level, leading to the discovery of new cell types and biomarkers valuable in disease diagnosis, response to therapy and treatment.
Single Cell Analysis Unit
Single Cell Analysis is an innovative technology that allows the evaluation of the genetic profile at a single cell level within a tissue, leading to the identification of specific biomarkers and the development of specialised diagnostic and therapeutic approaches.
Data Analysis, Integration and Modeling Unit
The Unit will provide bioinformatic and data analysis resources for individual medical genomic applications through the following pipelines:
Analysis of genetic variability
Individual epigenetic profiling
Efficient reference genome indexing
ExomeSeq data analysis
Clinical Samples Reception and Processing Unit
The Unit will determine strategies and
implement best practices for collecting, cataloguing, and storing samples and specimens (fresh, frozen or FFPE samples) for use in the above advanced technology platforms.
Cyclotron and PET Imaging Unit
The Unit will contribute to:
Identifying imaging biomarkers
Visualising molecular processes for early diagnosis
Identifying pathophysiological alterations when disease is present
Allowing diagnostic precision as well as treatment monitoring and response
Combining targeted imaging and therapy (theragnostics) and Individualising, image-guided therapeutic interventions
Soon to be included in pMedGR’s technologies.
This innovative technology recreates the natural physiology and mechanical forces experienced within the human body, thus providing a new standard for predicting how a human may respond to medicines, chemicals, and foods — with greater precision and control than today’s cell culture or animal-based testing methods.